Global Solid Tumor Drug Industry Growth and Trends Forecast to 2031
Description
Summary
According to APO Research, The global Solid Tumor Drug market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for Solid Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for Solid Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for Solid Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global companies of Solid Tumor Drug include Johnson & Johnson, Pfizer Inc, GlaxoSmithKline plc., Baxter, AstraZeneca, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Celgene Corporation and Bristol-Myers Squibb Company, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Solid Tumor Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Solid Tumor Drug.
The Solid Tumor Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Solid Tumor Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Solid Tumor Drug Segment by Company
Johnson & Johnson
Pfizer Inc
GlaxoSmithKline plc.
Baxter
AstraZeneca
F. Hoffmann-La Roche Ltd.
Eli Lilly and Company
Celgene Corporation
Bristol-Myers Squibb Company
Biogen
Amgen Limited & Amgen Ireland Limited
Abbott Laboratories
Solid Tumor Drug Segment by Type
Small Molecules
Biologics
Solid Tumor Drug Segment by Application
Radiology
Neurology
Oncology
Others
Solid Tumor Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Solid Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Solid Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Solid Tumor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Solid Tumor Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Solid Tumor Drug market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for Solid Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for Solid Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for Solid Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global companies of Solid Tumor Drug include Johnson & Johnson, Pfizer Inc, GlaxoSmithKline plc., Baxter, AstraZeneca, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Celgene Corporation and Bristol-Myers Squibb Company, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Solid Tumor Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Solid Tumor Drug.
The Solid Tumor Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Solid Tumor Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Solid Tumor Drug Segment by Company
Johnson & Johnson
Pfizer Inc
GlaxoSmithKline plc.
Baxter
AstraZeneca
F. Hoffmann-La Roche Ltd.
Eli Lilly and Company
Celgene Corporation
Bristol-Myers Squibb Company
Biogen
Amgen Limited & Amgen Ireland Limited
Abbott Laboratories
Solid Tumor Drug Segment by Type
Small Molecules
Biologics
Solid Tumor Drug Segment by Application
Radiology
Neurology
Oncology
Others
Solid Tumor Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Solid Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Solid Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Solid Tumor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Solid Tumor Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
101 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Solid Tumor Drug Market Size Overview by Region 2020 VS 2024 VS 2031
- 1.4 Global Solid Tumor Drug Market Size by Region (2020-2031)
- 1.4.1 Global Solid Tumor Drug Market Size by Region (2020-2025)
- 1.4.2 Global Solid Tumor Drug Market Size by Region (2026-2031)
- 1.5 Key Regions Solid Tumor Drug Market Size (2020-2031)
- 1.5.1 North America Solid Tumor Drug Market Size Growth Rate (2020-2031)
- 1.5.2 Europe Solid Tumor Drug Market Size Growth Rate (2020-2031)
- 1.5.3 Asia-Pacific Solid Tumor Drug Market Size Growth Rate (2020-2031)
- 1.5.4 South America Solid Tumor Drug Market Size Growth Rate (2020-2031)
- 1.5.5 Middle East & Africa Solid Tumor Drug Market Size Growth Rate (2020-2031)
- 2 Solid Tumor Drug Market by Type
- 2.1 Type Introduction
- 2.1.1 Small Molecules
- 2.1.2 Biologics
- 2.2 Global Solid Tumor Drug Market Size by Type
- 2.2.1 Global Solid Tumor Drug Market Size Overview by Type (2020-2031)
- 2.2.2 Global Solid Tumor Drug Historic Market Size Review by Type (2020-2025)
- 2.2.3 Global Solid Tumor Drug Market Size Forecasted by Type (2026-2031)
- 2.3 Global Solid Tumor Drug Market Size by Regions
- 2.3.1 North America Solid Tumor Drug Market Size Breakdown by Type (2020-2025)
- 2.3.2 Europe Solid Tumor Drug Market Size Breakdown by Type (2020-2025)
- 2.3.3 Asia-Pacific Solid Tumor Drug Market Size Breakdown by Type (2020-2025)
- 2.3.4 South America Solid Tumor Drug Market Size Breakdown by Type (2020-2025)
- 2.3.5 Middle East and Africa Solid Tumor Drug Market Size Breakdown by Type (2020-2025)
- 3 Solid Tumor Drug Market by Application
- 3.1 Type Introduction
- 3.1.1 Radiology
- 3.1.2 Neurology
- 3.1.3 Oncology
- 3.1.4 Others
- 3.2 Global Solid Tumor Drug Market Size by Application
- 3.2.1 Global Solid Tumor Drug Market Size Overview by Application (2020-2031)
- 3.2.2 Global Solid Tumor Drug Historic Market Size Review by Application (2020-2025)
- 3.2.3 Global Solid Tumor Drug Market Size Forecasted by Application (2026-2031)
- 3.3 Global Solid Tumor Drug Market Size by Regions
- 3.3.1 North America Solid Tumor Drug Market Size Breakdown by Application (2020-2025)
- 3.3.2 Europe Solid Tumor Drug Market Size Breakdown by Application (2020-2025)
- 3.3.3 Asia-Pacific Solid Tumor Drug Market Size Breakdown by Application (2020-2025)
- 3.3.4 South America Solid Tumor Drug Market Size Breakdown by Application (2020-2025)
- 3.3.5 Middle East and Africa Solid Tumor Drug Market Size Breakdown by Application (2020-2025)
- 4 Global Market Dynamics
- 4.1 Solid Tumor Drug Industry Trends
- 4.2 Solid Tumor Drug Industry Drivers
- 4.3 Solid Tumor Drug Industry Opportunities and Challenges
- 4.4 Solid Tumor Drug Industry Restraints
- 5 Competitive Insights by Company
- 5.1 Global Top Players by Solid Tumor Drug Revenue (2020-2025)
- 5.2 Global Solid Tumor Drug Industry Company Ranking, 2023 VS 2024 VS 2025
- 5.3 Global Solid Tumor Drug Key Company Headquarters & Area Served
- 5.4 Global Solid Tumor Drug Company, Product Type & Application
- 5.5 Global Solid Tumor Drug Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Solid Tumor Drug Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Solid Tumor Drug Players Market Share by Revenue in 2024
- 5.6.3 2024 Solid Tumor Drug Tier 1, Tier 2, and Tier 3
- 6 Company Profiles
- 6.1 Johnson & Johnson
- 6.1.1 Johnson & Johnson Comapny Information
- 6.1.2 Johnson & Johnson Business Overview
- 6.1.3 Johnson & Johnson Solid Tumor Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.1.4 Johnson & Johnson Solid Tumor Drug Product Portfolio
- 6.1.5 Johnson & Johnson Recent Developments
- 6.2 Pfizer Inc
- 6.2.1 Pfizer Inc Comapny Information
- 6.2.2 Pfizer Inc Business Overview
- 6.2.3 Pfizer Inc Solid Tumor Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.2.4 Pfizer Inc Solid Tumor Drug Product Portfolio
- 6.2.5 Pfizer Inc Recent Developments
- 6.3 GlaxoSmithKline plc.
- 6.3.1 GlaxoSmithKline plc. Comapny Information
- 6.3.2 GlaxoSmithKline plc. Business Overview
- 6.3.3 GlaxoSmithKline plc. Solid Tumor Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.3.4 GlaxoSmithKline plc. Solid Tumor Drug Product Portfolio
- 6.3.5 GlaxoSmithKline plc. Recent Developments
- 6.4 Baxter
- 6.4.1 Baxter Comapny Information
- 6.4.2 Baxter Business Overview
- 6.4.3 Baxter Solid Tumor Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.4.4 Baxter Solid Tumor Drug Product Portfolio
- 6.4.5 Baxter Recent Developments
- 6.5 AstraZeneca
- 6.5.1 AstraZeneca Comapny Information
- 6.5.2 AstraZeneca Business Overview
- 6.5.3 AstraZeneca Solid Tumor Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.5.4 AstraZeneca Solid Tumor Drug Product Portfolio
- 6.5.5 AstraZeneca Recent Developments
- 6.6 F. Hoffmann-La Roche Ltd.
- 6.6.1 F. Hoffmann-La Roche Ltd. Comapny Information
- 6.6.2 F. Hoffmann-La Roche Ltd. Business Overview
- 6.6.3 F. Hoffmann-La Roche Ltd. Solid Tumor Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.6.4 F. Hoffmann-La Roche Ltd. Solid Tumor Drug Product Portfolio
- 6.6.5 F. Hoffmann-La Roche Ltd. Recent Developments
- 6.7 Eli Lilly and Company
- 6.7.1 Eli Lilly and Company Comapny Information
- 6.7.2 Eli Lilly and Company Business Overview
- 6.7.3 Eli Lilly and Company Solid Tumor Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.7.4 Eli Lilly and Company Solid Tumor Drug Product Portfolio
- 6.7.5 Eli Lilly and Company Recent Developments
- 6.8 Celgene Corporation
- 6.8.1 Celgene Corporation Comapny Information
- 6.8.2 Celgene Corporation Business Overview
- 6.8.3 Celgene Corporation Solid Tumor Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.8.4 Celgene Corporation Solid Tumor Drug Product Portfolio
- 6.8.5 Celgene Corporation Recent Developments
- 6.9 Bristol-Myers Squibb Company
- 6.9.1 Bristol-Myers Squibb Company Comapny Information
- 6.9.2 Bristol-Myers Squibb Company Business Overview
- 6.9.3 Bristol-Myers Squibb Company Solid Tumor Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.9.4 Bristol-Myers Squibb Company Solid Tumor Drug Product Portfolio
- 6.9.5 Bristol-Myers Squibb Company Recent Developments
- 6.10 Biogen
- 6.10.1 Biogen Comapny Information
- 6.10.2 Biogen Business Overview
- 6.10.3 Biogen Solid Tumor Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.10.4 Biogen Solid Tumor Drug Product Portfolio
- 6.10.5 Biogen Recent Developments
- 6.11 Amgen Limited & Amgen Ireland Limited
- 6.11.1 Amgen Limited & Amgen Ireland Limited Comapny Information
- 6.11.2 Amgen Limited & Amgen Ireland Limited Business Overview
- 6.11.3 Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.11.4 Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Product Portfolio
- 6.11.5 Amgen Limited & Amgen Ireland Limited Recent Developments
- 6.12 Abbott Laboratories
- 6.12.1 Abbott Laboratories Comapny Information
- 6.12.2 Abbott Laboratories Business Overview
- 6.12.3 Abbott Laboratories Solid Tumor Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.12.4 Abbott Laboratories Solid Tumor Drug Product Portfolio
- 6.12.5 Abbott Laboratories Recent Developments
- 7 North America
- 7.1 North America Solid Tumor Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 7.2 North America Solid Tumor Drug Market Size by Country (2020-2025)
- 7.3 North America Solid Tumor Drug Market Size Forecast by Country (2026-2031)
- 8 Europe
- 8.1 Europe Solid Tumor Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 8.2 Europe Solid Tumor Drug Market Size by Country (2020-2025)
- 8.3 Europe Solid Tumor Drug Market Size Forecast by Country (2026-2031)
- 9 Asia-Pacific
- 9.1 Asia-Pacific Solid Tumor Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 9.2 Asia-Pacific Solid Tumor Drug Market Size by Country (2020-2025)
- 9.3 Asia-Pacific Solid Tumor Drug Market Size Forecast by Country (2026-2031)
- 10 South America
- 10.1 South America Solid Tumor Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 10.2 South America Solid Tumor Drug Market Size by Country (2020-2025)
- 10.3 South America Solid Tumor Drug Market Size Forecast by Country (2026-2031)
- 11 Middle East & Africa
- 11.1 Middle East & Africa Solid Tumor Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 11.2 Middle East & Africa Solid Tumor Drug Market Size by Country (2020-2025)
- 11.3 Middle East & Africa Solid Tumor Drug Market Size Forecast by Country (2026-2031)
- 12 Concluding Insights
- 13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
